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Heart failure is a leading cause of death in humans, and stress is
increasingly associated with adverse cardiac outcomes. Gluco-
corticoids are primary stress hormones, but their direct role in
cardiovascular health and disease is poorly understood. To de-
termine the in vivo function of glucocorticoid signaling in the
heart, we generated mice with cardiomyocyte-specific deletion
of the glucocorticoid receptor (GR). These mice are born at the
expected Mendelian ratio, but die prematurely from spontaneous
cardiovascular disease. By 3 mo of age, mice deficient in cardio-
myocyte GR display a marked reduction in left ventricular systolic
function, as evidenced by decreases in ejection fraction and
fractional shortening. Heart weight and left ventricular mass are
elevated, and histology revealed cardiac hypertrophy without
fibrosis. Removal of endogenous glucocorticoids and mineralocorti-
coids neither augmented nor lessened the hypertrophic response.
Global gene expression analysis of knockout hearts before pathol-
ogy onset revealed aberrant regulation of a large cohort of genes
associated with cardiovascular disease as well as unique disease
genes associated with inflammatory processes. Genes important for
maintaining cardiac contractility, repressing cardiac hypertrophy,
promoting cardiomyocyte survival, and inhibiting inflammation
had decreased expression in the GR-deficient hearts. These findings
demonstrate that a deficiency in cardiomyocyte glucocorticoid sig-
naling leads to spontaneous cardiac hypertrophy, heart failure, and
death, revealing an obligate role for GR in maintaining normal car-
diovascular function. Moreover, our findings suggest that selective
activation of cardiomyocyte GR may represent an approach for the
prevention of heart disease.
Heart failure is one of the leading causes of morbidity andmortality in developed countries. Well-known risk factors
for cardiovascular disease include hypertension, diabetes, obesity,
physical inactivity, and smoking. In addition to these conven-
tional factors, stress is increasingly recognized for its important
contribution to the development and progression of cardiac
disease (1, 2). One of the major biological systems activated
during the stress response is the hypothalamic–pituitary–adrenal
axis (HPA). Activation of the HPA axis results in the release of
glucocorticoids from the adrenal gland, and these hormones
function to maintain homeostasis in the face of internal or ex-
ternal challenges. As the primary stress hormone in humans,
glucocorticoids act on numerous target tissues to regulate a
plethora of biological processes. Because of their potent anti-
inflammatory and immunosuppressive actions, synthetic gluco-
corticoids are also widely used in the clinic to treat inflammation,
autoimmune diseases, and hematological cancers. Despite a
wealth of information regarding the function of glucocorticoids
and the widespread therapeutic use of these steroids, the direct
biological actions of glucocorticoids in the heart remain poorly
understood.
The physiological and pharmacological actions of glucocorti-
coids are mediated by the glucocorticoid receptor (GR; NR3C1),
a member of the nuclear receptor superfamily of ligand-
dependent transcription factors. Upon glucocorticoid occupancy,
GR regulates the expression of thousands of genes by direct
binding to DNA and/or by interactions with other chromatin-
bound transcription factors (3). Global inactivation of the GR
gene in mice leads to perinatal lethality (4). Therefore, to elu-
cidate the role of glucocorticoid signaling in the heart, we gen-
erated mice specifically lacking GR in cardiomyocytes. These
mice exhibit profound alterations in gene expression profiles that
lead to left ventricular (LV) systolic dysfunction, cardiac hyper-
trophy, heart failure, and death, revealing a crucial role for
cardiomyocyte GR signaling in the function of the heart.
Results
Floxed GR mice (GRloxP/loxP) were generated by standard gene-
targeting techniques and contain loxP sites flanking exons 3 and
4 of the GR gene (Fig. 1A). These mice were crossed with mice
expressing Cre recombinase under the control of the alpha myosin
heavy chain promoter (αMHCCre/+) to specifically delete GR in
cardiomyocytes (5). Cre-mediated deletion of exons 3 and 4,
which encode the DNA-binding domain of GR, not only gen-
erates a null GR allele but also results in a frameshift mutation
and premature stop codon if splicing occurs between exons
2 and 5. CardioGRKO mice (GRloxP/loxPαMHCCre/+) were born
at the expected Mendelian ratio, and Cre-mediated recombi-
nation was detected only in heart tissue (Fig. 1A). Cre-negative
littermates (GRloxP/loxPαMHC+/+) were used as controls in our
studies. Compared with control mice, GR mRNA was signifi-
cantly decreased in the hearts from cardioGRKO mice (Fig. 1B).
The residual level of GR mRNA likely reflects its expression in
other cell types of the heart. Immunoblots of whole-heart lysates
showed a marked reduction in the level of GR protein from the
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cardioGRKO mice (Fig. 1C), and immunohistochemistry re-
vealed that the decrease in GR expression was confined to car-
diomyocytes (Fig. 1D). In contrast to GR, no differences were
observed in the expression level of the closely related min-
eralocorticoid receptor (MR) (Fig. 1 B and C). To determine
whether glucocorticoid responsiveness was diminished, we trea-
ted cardioGRKO mice with the synthetic glucocorticoid dexa-
methasone for 6 h and evaluated the regulation of three genes
classically induced by activated GR. FK506-binding protein 5
(Fkbp5) functions to modulate GR activity, and both lipocalin
2 (Lcn2) and zinc finger protein 36 (Zfp36) inhibit the in-
flammatory response. Compared with littermate controls, the
dexamethasone-dependent induction of these three genes was
greatly impaired in the cardioGRKO mice (Fig. 2). The small
glucocorticoid-dependent increase in Lcn2 and Zfp36 expression
in the cardioGRKO mice did not reach statistical significance,
and likely reflects glucocorticoid signaling in other cells of the
heart where GR expression remains intact.
The cardioGRKO mice appeared normal early in life, but by
∼5 mo of age began exhibiting increased morbidity and mortal-
ity. Kaplan–Meier survival curves reveal a reduced life span for
the cardioGRKO mice, as their median survival age was only 7
mo (Fig. 3). Male mice had a median survival age of 8 mo, and
female mice had a median survival age of 6 mo (Fig. 3). A trend
(P = 0.0689, female vs. male mice) for the shorter life span in
females suggests that the susceptibility to the detrimental effects
of inactivation of GR signaling in cardiomyocytes may exhibit
some degree of sexual dimorphism. Of the 41 cardioGRKO mice
that died prematurely, 17 were found dead in their cage and 24
were euthanized after showing symptoms of respiratory distress.
Nearly all of the necropsied mice had enlarged hearts, and the
majority had excess fluid in the thoracic cavity (Fig. 4A). Heart
sections from cardioGRKO mice euthanized at 6 mo of age due
to labored breathing showed marked dilation of the left ventricle
(Fig. 4B, Left). Atrial thrombosis characterized by lamellation
of fibrin and inflammatory cells, chronic inflammation, neo-
vascularization, and fibrosis was also observed, and is consistent
with atrial blood stasis and chronic heart failure (Fig. 4B, Left
and SI Appendix, Fig. S1A). Moreover, lungs from these mice
exhibited free erythrocytes in alveoli and hemosiderin-laden
macrophages (heart failure cells) within alveolar spaces (Fig. 4B,
Right). These findings suggest that the cardioGRKO mice are
dying from heart failure.
To better understand the cardiac pathology underlying the
spontaneous death, we evaluated the hearts of the cardioGRKO
mice by conscious transthoracic echocardiography. No major
differences were observed between 1-mo-old control and car-
dioGRKO mice (SI Appendix, Table S1). However, by 3 mo,
a distinct cardiac phenotype emerged. Mice deficient in cardiac
GR exhibited spontaneous LV systolic dysfunction, as evidenced
by significant decreases in ejection fraction (87.3% control vs.
71.7% cardioGRKO) and fractional shortening (55.5% control
vs. 40.5% cardioGRKO) (Table 1). Representative motion mode
(M-mode) images clearly depict the altered LV end-systolic di-
mension in the cardioGRKO mice (Fig. 4C). Paralleling the
observed functional deficits, we measured an increase in the size
of the GR-deficient hearts. Both heart weight and LV mass
adjusted to tibia length and body weight, respectively, were sig-
nificantly elevated in the cardioGRKO mice (Table 1). Consis-
tent with the age range over which the cardioGRKO mice died,
variability was observed in the progression of the heart pathol-
ogy. Of the nine cardioGRKO mice analyzed in Table 1, two of
the 6-mo-old mice had large hearts but normal systolic function
(prefailure), and seven of the mice had systolic dysfunction
consistent with advanced heart failure. Separate analysis of the
seven more severely affected mice revealed an even greater re-
duction in ejection fraction (87.3% control vs. 67.6% car-
dioGRKO) and fractional shortening (55.5% control vs. 36.7%
cardioGRKO) (SI Appendix, Table S2). It has been suggested
that high levels of Cre expression in cardiomyocytes can lead to
cardiac toxicity in mice older than those used in our studies (6).
Thus, we performed echocardiography on mice expressing Cre
alone (GR+/+αMHCCre/+). Our data showed no significant effect
on any of the echocardiographic indices measured in Cre-only
mice up to 6 mo of age (SI Appendix, Table S3), indicating that
the impaired cardiac function in 3- to 6-mo-old cardioGRKO
mice is due to the loss of GR.
Hearts from the cardioGRKO mice were further analyzed by
histology to investigate the molecular basis of the increased LV
mass. A pronounced thickening was apparent in the ventricular
walls of 3-mo-old cardioGRKO mice (Fig. 4D). No fibrosis was
detected in the GR-deficient hearts (SI Appendix, Fig. S1B);
however, there was an ∼140% increase in cardiomyocyte cross-
sectional area (Fig. 4E). Interestingly, the cardiac remodeling
and compromised heart function in the cardioGRKO mice 3–6
mo of age were not associated with any electrocardiogram ab-






































































Control CardioGRKO Control CardioGRKO Control CardioGRKO
Wildtype GR
Floxed GR
1 5 763 4 8 92
1 5 763 4 8 92
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Fig. 1. Generation of mice with conditional knockout of GR in car-
diomyocytes. (A) (Upper) Mice deficient in GR specifically in cardiomyocytes
(cardioGRKO) were generated by crossing mice with a floxed GR allele
(GRloxP,loxP) with mice expressing Cre recombinase only in cardiomyocytes
(αMHCCre/+). Cre-mediated deletion of exons 3 and 4 results in a null GR
allele. A frameshift mutation and premature stop codon result if splicing
occurs between exons 2 and 5. (Lower) Cre-mediated recombination is spe-
cific to the hearts of cardioGRKO mice. DNA from various tissues of car-
dioGRKO mice was subjected to PCR using primers that detect the floxed
GR allele (lane 1) and the null GR allele (lane 2). M, size marker. (B) RT-PCR of
GR and MR mRNA from hearts of control and cardioGRKO mice. Data are
mean ± SEM (n = 3–4 mice per group). **P < 0.01, ***P < 0.001 vs. control
mice. (C) Representative immunoblot of GR and MR protein from hearts
of control and cardioGRKO mice. (D) Representative immunofluorescence
staining of heart sections from control and cardioGRKO mice with anti-
GR antibody.
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mice adrenalectomized at 2 mo to remove endogenous gluco-
corticoids and mineralocorticoids and then aged for an ad-
ditional 4 mo exhibited an increase in cardiomyocyte size
comparable to that observed in intact cardioGRKO mice (SI
Appendix, Fig. S1C), suggesting that unabated MR signaling in
the cardiomyocytes did not contribute to the pathology. Col-
lectively, these data suggest that GR deficiency in mouse car-
diomyocytes leads to spontaneous cardiac hypertrophy and
concomitant LV dysfunction that is consistent with heart failure.
A hallmark of pathological cardiac hypertrophy and heart
failure is the expression of certain fetal genes in the adult heart.
In the hearts of the cardioGRKO mice, we found age-dependent
increases in β-myosin heavy chain (βMHC) and skeletal muscle
α-actin (SKA) that reached 8-fold and 12.1-fold, respectively,
over control mice by 3 mo of age (SI Appendix, Fig. S2A). Other
hypertrophic marker genes were also dysregulated in the GR-
deficient hearts. We measured a 3.1-fold increase in brain na-
triuretic peptide (BNP), a 2.4-fold increase in smooth muscle
α-actin (SMA), and a 40% reduction in αMHC (SI Appendix, Fig.
S2B). These findings indicate that the observed cardiac hyper-
trophy in the cardioGRKO mice is mechanistically pathological.
To define the molecular events and biological pathways un-
derlying the cardiac pathology, we performed a genome-wide
microarray analysis on hearts from control and cardioGRKO
mice that were 1, 2, or 3 mo of age. The younger 1- and 2-mo-old
mice were chosen because they permit an assessment of the
genetic changes in the heart that precede, and potentially give
rise to, the cardiac dysfunction observed in 3-mo-old mice. Ab-
lation of GR resulted in the differential expression of 302, 1,189,
and 925 genes in the hearts from knockout mice that were 1, 2, or
3 mo old, respectively (Fig. 5A and SI Appendix, Table S5). The
majority of genes showed decreased levels of mRNA in mice 1 or
2 mo of age, suggesting that GR signaling is necessary to main-
tain their expression. At the 3-mo time point, when heart dys-
function was evident, a large number of genes showed increased
levels of mRNA. These later changes may be secondary to the
developing pathology, and they suggest that GR signaling is
important for limiting the expression of many genes in the nor-
mal heart. Analysis of the differentially expressed genes at each
time point by literature-based Ingenuity Pathway Analysis (IPA)
software identified “cardiovascular disease” as one of the top
biological functions most significantly affected by the altered
gene expression pattern in the cardioGRKO mice (Fig. 5B).
A total of 25, 112, and 105 genes associated with cardiovas-
cular disease were, respectively, dysregulated in hearts from
cardioGRKO mice that were 1, 2, and 3 mo of age (Fig. 5B and
SI Appendix, Table S6). Among the genes with diminished ex-
pression were dystrophin (Dmd), ryanodine receptor 2 (RyR2),
Kruppel-like factor 15 (Klf15), and the lipocalin-type prosta-
glandin D synthase (Ptgds). Dmd is a structural protein that links
the sarcomere to the extracellular matrix and is important for
cardiomyocyte contraction. RyR2 is a calcium channel that plays
a crucial role in cardiomyocyte contraction by mediating the
release of calcium from the sarcoplasmic reticulum. Klf15 is
a transcriptional regulator that functions to prevent cardiac hy-
pertrophy by repressing the activity of MEF2 and GATA4. Ptgds
is an enzyme responsible for prostaglandin D2 (PGD2) bio-
synthesis, and Ptgds-mediated production of PGD2 promotes
cardiomyocyte survival. By impairing cardiac contractility and
stimulating cardiac hypertrophy, the aberrant down-regulation of
these four genes may underlie and/or contribute to the observed
cardiomyopathy in the cardioGRKO mice. To independently
confirm the changes in these four genes, we performed RT-PCR
on hearts from additional cardioGRKO mice that were 1, 2, or
3 mo old. All four genes exhibit an age-dependent reduction in
expression that precedes the onset of the heart pathology in the
cardioGRKO mice (Fig. 6).
Decreases in the expression and function of RyR2 have been
associated with abnormal calcium handling in cardiac hypertro-
phy and heart failure (7). Consistent with the reduction in RyR2
mRNA (Fig. 6), RyR2 protein levels were also reduced in hearts
from cardioGRKO mice (SI Appendix, Fig. S3A). To determine
the functional consequence of the reduction in RyR2, we iso-
lated cardiomyocytes from adult control and cardioGRKO mice
and evaluated intracellular calcium changes following treatment
with the classic RyR2 activator caffeine (SI Appendix, Fig. S3B).
In response to low concentrations of caffeine (0.25 or 0.5 mM),
the majority of cardiomyocytes from control mice (10/12 cells,
83.3%) exhibited a pronounced and sustained increase in in-
tracellular calcium. In contrast, the majority of GR-deficient
cardiomyocytes (18/28 cells, 64.3%) showed no sustained in-
crease in intracellular calcium under these same conditions, but
did exhibit an increase in the frequency of calcium oscillations.
Both control and cardioGRKO cardiomyocytes all responded
with large and sustained increases in intracellular calcium upon
subsequent addition of a high concentration of caffeine (10 mM).
These data indicate that GR-deficient cardiomyocytes have re-
duced levels of RyR2 and altered sensitivity to caffeine-induced
intracellular calcium responses.
It is of great interest that the majority of the dysregulated
genes in the GR-deficient hearts have not been previously as-
sociated with cardiovascular disease. This finding suggests that
a deficiency in cardiomyocyte GR signaling may impact other
cellular pathways with novel roles in the pathogenesis of heart
failure. One of the most-established and clinically important
actions of glucocorticoids is to suppress the immune system and
inflammatory response. Examination of the dysregulated genes
in the knockout hearts by IPA revealed a strong association with
inflammation (Fig. 5B and SI Appendix, Table S7). Preceding the
development of cardiac pathology, there is a large increase in the



















































Fig. 2. Glucocorticoid regulation of target genes
is impaired in cardioGRKO mice. Control and car-
dioGRKO mice were injected intraperitoneally with
vehicle (con) or dexamethasone (dex; 1 mg/kg) for
6 h. Total RNA was isolated from whole hearts, and
RT-PCR was performed to measure Fkbp5, Lcn2, and
Zfp36 mRNA levels. Data are mean ± SEM (n = 3–5
mice per group). *P < 0.05, **P < 0.01, ***P < 0.001







































A B C Fig. 3. GR deficiency leads to premature death in
cardioGRKO mice. Kaplan–Meier analysis of survival
after birth was performed for control and car-
dioGRKO mice. Shown are survival curves for all
mice (A), males only (B), and females only (C). Data
are from 61 control mice (31 male, 30 female) and
54 cardioGRKO mice (23 male, 31 female). ***P <
0.001 vs. control mice.











number of genes associated with inflammation in 2-mo-old car-
dioGRKO mice (SI Appendix, Fig. S4). A further increase in the
number of dysregulated inflammatory genes is observed in 3-mo-
old cardioGRKO mice, when heart dysfunction is evident (SI
Appendix, Fig. S4). Moreover, there is a pronounced shift in the
proportion of these genes that are up-regulated, consistent with
an exaggerated immune response (SI Appendix, Fig. S4). Gene
Ontology (GO) analysis of the genes differentially expressed in
the cardioGRKO mice further substantiated the link to inflam-
mation (SI Appendix, Table S8). Both “inflammatory response”
and “immune response” were among the most significantly af-
fected annotations in cardioGRKO mice 1–3 mo of age. In fact,
inflammatory response was the top GO annotation associated
with the set of genes dysregulated in the hearts of 1-mo-old
cardioGRKO mice. Together, these data indicate that disruption
of GR signaling in the hearts of cardioGRKO mice leads to the
dysregulation of multiple genes and pathways with critical roles
in cardiomyocyte biology.
Discussion
The severe pathology that develops in the hearts of cardioGRKO
mice reveals an essential role for cardiomyocyte GR in normal
heart homeostasis. Glucocorticoids regulate thousands of genes
and impact numerous biological processes in cardiomyocytes (8).
Therefore, the etiology of the heart dysfunction in the car-
dioGRKO mice is likely to be multifaceted and result from the
combined dysregulation of many different genes. Indeed, global
gene expression analysis of the cardioGRKO mouse hearts be-
fore pathology onset identified aberrant expression profiles for
130 genes known to be associated with cardiovascular disease
and over 1,000 genes not previously associated with heart dys-
function. We further characterized the aberrant down-regulation
of a key set of genes important for the contraction of the heart
(Dmd and RyR2), for repressing the hypertrophic program
(Klf15), and for promoting the survival of cardiomyocytes
(Ptgds). All four genes show an age-dependent decline in ex-
pression that precedes the onset of the cardiomyopathy in the
cardioGRKO mice. The reduced expression of RyR2 leads to
altered calcium responses in GR-deficient cardiomyocytes.
Consistent with the phenotype of the cardioGRKO mice, ab-
normal calcium handling, cardiac hypertrophy, and systolic dys-
function have been reported in RyR2-deficient mice (9, 10).
Knockout of RyR2 can also lead to fatal arrhythmias (9), sug-
gesting that the cardioGRKO mice may exhibit acute episodes of
abnormal heart rhythms at the time of death. Changes in the
expression of other genes may also play an important role in the
pathogenesis of the cardiac dysfunction in the cardioGRKO
mice. For example, the ubiquitin ligase muscle ring finger protein
1 (MuRF1) is a negative regulator of cardiac hypertrophy that is
significantly repressed in GR knockout hearts (SI Appendix,
Table S6). Whether the Dmd and RyR2 genes are primary or
secondary targets of GR regulation is currently unknown. However,
Klf15, Ptgds, and MuRF1 are bona fide glucocorticoid-responsive
target genes that are induced by activated GR (11–14). Ac-
cordingly, in the absence of an intact GR signaling pathway in
cardiomyocytes, the expression of these genes is significantly
repressed.
Inflammatory processes are involved in many conditions that
injure the myocardium and cause both structural and functional
defects in the heart (15, 16), and glucocorticoids have well-
documented anti-inflammatory actions. Examination of the
genes dysregulated in the hearts of the cardioGRKO mice by
both IPA and GO revealed a prominent association with the
immune response and inflammation. Among the dysregulated
immunomodulatory genes is Lcn2. Lcn2 is known to be induced
by activated GR and can function to inhibit chemokine expres-
sion and restrain inflammation. In the hearts of the car-
dioGRKO mice, exogenous glucocorticoid regulation of Lcn2 is
impaired and the basal expression of this gene is reduced (Fig. 2
and SI Appendix, Table S5). Similar findings were observed for
Fig. 4. Heart pathology and dysfunction in cardioGRKO mice. (A) Repre-
sentative images of intact hearts from 6-mo-old control and cardioGRKO
mice. (B) Representative images of H&E-stained sections of heart (Left) and
lungs (Right) from a 6-mo-old cardioGRKO mouse. Indicated are left atrial
thrombus with lamellated fibrin (asterisk), erythrocytes in alveoli (black
arrowhead), and hemosiderin-laden macrophages (white arrowhead). (C)
Representative M-mode images from 3-mo-old control and cardioGRKO
mice. (D) Representative images of H&E-stained sections of 3-mo-old control
and cardioGRKO hearts. (E) Representative images of Masson’s trichrome
staining of cardiomyocytes from 3-mo-old control and cardioGRKO mice
and morphometric analysis of cardiomyocyte cross-sectional area. Data are
mean ± SEM (n = 4 mice per group). ***P < 0.001 vs. control mice.
Table 1. Echocardiography on control and cardioGRKO mice
Parameter Control, n = 10 CardioGRKO, n = 9
IVSTD, mm 1.09 ± 0.02 1.14 ± 0.01
LVEDD, mm 3.02 ± 0.10 3.23 ± 0.04
PWTD, mm 1.01 ± 0.02 1.03 ± 0.02
IVSTS, mm 1.72 ± 0.03 1.72 ± 0.02
LVESD, mm 1.34 ± 0.05 1.93 ± 0.04***
PWTS, mm 1.56 ± 0.04 1.49 ± 0.02
LV VolD, μL 36.11 ± 3.08 42.9 ± 1.2
LV VolS, μL 4.64 ± 0.44 12.6 ± 0.6***
EF, % 87.3 ± 0.3 71.7 ± 0.9***
FS, % 55.5 ± 0.3 40.5 ± 0.8***
LV mass, mg 112.65 ± 6.65 132.0 ± 3.0*
Tibia length, mm 17.23 ± 0.13 17.20 ± 0.03
Heart weight, mg 119.5 ± 4.5 141.5 ± 2.7***
HW/BW, mg/g 3.54 ± 0.18 4.44 ± 0.10***
HW/TL, mg/mm 6.9 ± 0.2 8.2 ± 0.2***
LV mass/BW, mg/g 3.3 ± 0.1 3.7 ± 0.1**
LV mass/TL, mg/mm 6.5 ± 0.3 7.7 ± 0.2*
HR, bpm 668 ± 13 644 ± 5
BW, g 28.3 ± 2.7 33.2 ± 0.5
Echocardiographic measurements from transthoracic M-mode tracings on
conscious male mice 3–6 mo of age. Data are mean ± SEM. bpm, beats per
min; BW, body weight; EF, ejection fraction; FS, fractional shortening; HR,
heart rate; HW, heart weight; IVSTD, interventricular septal thickness in di-
astole; IVSTS, interventricular septal thickness in systole; LV VolD, LV volume
in diastole; LV VolS, LV volume in systole; LVEDD, LV end-diastolic dimen-
sion; LVESD, LV end-systolic dimension; PWTD, posterior wall thickness in
diastole; PWTS, posterior wall thickness in systole; TL, tibia length. A Student
t test was performed to determine significance. Values without asterisks
were not significantly different. *P < 0.05, **P < 0.01, ***P < 0.001 vs.
control mice.
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the Zfp36 gene, whose protein product, tristetraprolin, desta-
bilizes the mRNA for many proinflammatory cytokines. Gluco-
corticoid induction of Zfp36 is abrogated and basal levels are
decreased in GR-deficient hearts (Fig. 2 and SI Appendix, Table
S5). Failure of endogenous glucocorticoids to maintain appro-
priate expression of these and other immunomodulatory genes
may lead to excessive and persistent activation of inflammatory
processes that underlie and/or exacerbate the severity of the heart
pathology in the cardioGRKOmice. Gross histological evidence for
increased inflammation was not observed in young cardioGRKO
mice, suggesting these immune changes may become more prom-
inent as the mice age.
Some of the genetic changes detected in the 1-, 2-, and 3-mo-old
cardioGRKO mice may be secondary to the inappropriate regula-
tion of glucocorticoid-responsive target genes at an earlier time. In
an effort to capture these primary genes, we also performed a ge-
nome-wide microarray on neonatal hearts from control and car-
dioGRKO mice (SI Appendix, Fig. S5). As observed in GR
knockout mice 1 or 2 mo of age (Fig. 5), the majority of dysregu-
lated genes showed decreased expression, and IPA identified car-
diovascular disease as one of the top biological functions most
significantly affected by ablation of GR. Strikingly, more than one-
third of the 49 genes associated with cardiovascular disease that
were aberrantly expressed in hearts from neonatal cardioGRKO
mice have been shown in the literature to be regulated by glu-
cocorticoids. These GR target genes include many transcrip-
tion factors and plasma membrane receptors, as well as
several intracellular proteins involved in GPCR and MAPK
signal transduction pathways. Reduced expression of one or
more of these primary genes may lead to subsequent alterations
in the expression profile of other secondary genes that contribute
to the pathology in the cardioGRKO mice.
In addition to GR, cardiomyocytes express the closely related
mineralocorticoid receptor that binds aldosterone and gluco-
corticoids with similar high affinity. Glucocorticoids typically
circulate at much higher levels than aldosterone, and cardiac-
specific MR is thought to be primarily occupied by glucocorti-
coids under normal physiological conditions. To assess whether
glucocorticoid activation of MR contributes to the heart failure
phenotype observed in the cardioGRKO mice, we removed cir-
culating glucocorticoids in these mice by surgical excision of the
adrenal glands. Adrenalectomy neither augmented nor lessened
the hypertrophic response in the cardioGRKO mice, suggesting
the cardiac dysfunction is mediated solely by a deficiency in


















































































































































































Fig. 5. Global gene expression profile in hearts from cardioGRKO mice.
Microarray analysis was performed on RNA from the hearts of 1-, 2-, and
3-mo-old control and cardioGRKO mice. (A) Total number of genes differ-
entially expressed in the hearts of cardioGRKO mice compared with control
littermates (ANOVA, P < 0.01). (B) Differentially expressed genes were an-
alyzed by IPA software for each age group. Shown are the top 10 biological
functions most significantly associated with the genes differentially regu-
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Fig. 6. Down-regulation of genes associated with cardiovascular disease in
the hearts of cardioGRKO mice. Total RNA was isolated from whole hearts of
control and cardioGRKO mice 1, 2, or 3 mo of age. Dmd, RyR2, Klf15, and
Ptgds mRNA levels were measured by RT-PCR. Data are mean ± SEM (n = 3–5
mice per group). *P < 0.05, **P < 0.01, ***P < 0.001 vs. control mice.











In agreement with our findings in the cardioGRKO mice are
several independent lines of evidence that suggest that GR sig-
naling is important for maintaining normal heart function in
humans. For example, persons with a polymorphism (A3669G)
in the GR gene resulting in increased expression of the domi-
nant-negative receptor variant GRβ and concomitant glucocor-
ticoid resistance have an increased risk of coronary artery
disease, enlarged hearts, systolic dysfunction, and heart failure
(17–19). In addition, patients with Addison disease, a life-
threatening disorder characterized by decreased production of
glucocorticoids, present with weak hearts (20). Although heart
failure secondary to Addison disease has been described (21),
cardiac hypertrophy has not been reported, perhaps reflecting
the diagnosis and effective treatment of individuals before car-
diac abnormalities become severe (22). Alternatively, because
Addison disease operates at a systemic level and is also accom-
panied by insufficient mineralocorticoid signaling, the resulting
heart pathology in these patients may differ from the cardiac
abnormalities detected in the cardioGRKO mice, where gluco-
corticoid signaling is deficient only in cardiomyocytes.
Heart failure remains one of the leading causes of mortality in
the Western world, and stress is increasingly recognized as a con-
tributing factor to cardiac disease. The stress-induced rise in glu-
cocorticoids may benefit the heart in the short term by the direct
actions of glucocorticoids on cardiomyocytes that improve their
contractility and promote their survival. However, sustained
increases in glucocorticoids negatively impact heart function via
the systemic actions of glucocorticoids on noncardiac tissues that
lead to hypertension and metabolic syndrome. Progress has been
made in understanding the molecular basis for heart failure and in
developing therapeutic agents to combat its progression, yet the
clinical outcome for heart failure patients remains poor. Using
mice deleted of GR specifically in cardiomyocytes, we have dis-
covered that a deficiency in cardiomyocyte GR signaling leads to
spontaneous cardiac hypertrophy, LV dysfunction, heart failure,
and death. These findings reveal an obligate role for GR in
maintaining normal heart function, and suggest that activating GR
signaling selectively in cardiomyocytes through local delivery of
glucocorticoids to the myocardium may provide an attractive ap-
proach for treating heart disease.
Materials and Methods
Please see SI Appendix, Materials and Methods for details.
Generation of CardioGRKOMice. The mouse GR (NR3C1) locus was modified by
insertion of loxP sites upstream of exon 3 and downstream of exon 4 by
standard gene-targeting procedures. Mice harboring the modified GR allele
were derivedby blastocyst (albinoB6) injection.Mice homozygous for thefloxed
GR allele (GRloxP,loxP) were mated with mice expressing Cre recombinase under
the direction of cardiomyocyte-specific αMHCCre/+ (5). The resulting offspring,
on a mixed C57BL/6 and FVB/N background, were GRloxP/loxPαMHCCre/+
mice (designated cardioGRKO) and Cre-negative GRloxP/loxPαMHC+/+ litter-
mate mice that served as controls. All experiments were approved and
performed according to the guidelines of the Animal Care and Use Com-
mittees at the University of North Carolina at Chapel Hill and the National
Institute of Environmental Health Sciences (NIEHS), National Institutes of
Health (NIH).
Real-Time PCR. Total RNA was isolated from the whole hearts of control and
cardioGRKO mice, and the abundance of mRNAs was determined on a
7900HT sequence detection system (Applied Biosystems).
Immunoblotting. Hearts from control and cardioGRKO mice were lysed in
RIPA buffer. Membranes with equivalent amounts of protein were incubated
with primary antibodies and developed by enhanced chemiluminescence
(GE Healthcare).
Histological Analysis. Hearts from control and cardioGRKO mice were per-
fused with PBS and fixed with paraformaldehyde. Samples were stained with
H&E or Masson’s trichrome or processed for immunohistochemistry.
Survival Analysis. Control and cardioGRKO mice were monitored on a daily
basis for morbidity or death until 12 mo of age.
Echocardiographic Analysis. Transthoracic echocardiography was performed
on conscious mice using a Vevo 770 ultrasound biomicroscopy system
(VisualSonics).
Microarray Analysis. Gene expression analysis was performed on RNA from
hearts of control and cardioGRKO mice using Whole Mouse Genome oligo
arrays (014868) (Agilent Technologies). Significant changes in gene expres-
sion were defined on the basis of P value (P < 0.01). Specifically, an error-
weighted ANOVA and Benjamini–Hochberg multiple test correction were
performed using the Rosetta Resolver system (Rosetta Biosoftware). Signif-
icantly regulated genes were analyzed by IPA (Ingenuity Systems) and by
GO. Gene enrichment P values (P < 0.05) for biological functions were de-
termined by IPA using Fisher’s exact test.
Statistical Analysis. A Student t test or one-way ANOVA with Tukey’s post hoc
analysis was used to evaluate whether differences between groups were
statistically significant. For Kaplan–Meier survival curves, the log-rank test
was used. Statistical significance was defined as P < 0.05.
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